Study characteristics
| . | . | . | . | . | . | VTE, n/N (%) . | Major bleeding, n/N (%) . | All-cause mortality, n/N (%) . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study . | Design . | Intervention . | Cancer type . | Randomized patients, n . | Khorana score ≥2, n (%) . | Prophylaxis . | Control . | Prophylaxis . | Control . | Prophylaxis . | Control . |
| CASSINI (2019)15 | Double blind | DOAC: rivaroxaban (10 mg) OD for 6 mo | Solid tumor or lymphoma | 841 | 841 (100) | 25/420 (6) | 37/421 (9) | 8/405 (2) | 4/404 (1) | 84/420 (20) | 100/421 (24) |
| AVERT (2019)14 | Double blind | DOAC: apixaban (2.5 mg) BID for 6 mo | Various types of new diagnoses or progressive solid cancers | 574 | 574 (100) | 12/291 (4) | 28/283 (10) | 6/288 (2) | 3/275 (1) | 35/291 (12) | 27/283 (10) |
| FRAGMATIC (2016)38 | Open label | LMWH: dalteparin (5000 IU) OD for 24 wk | Primary bronchial small-cell or non–small-cell carcinoma | 2202 | 1,343 (61) | 26/654 (4) | 45/689 (7) | 9/654 (2) | 13/689 (2) | 219/654 (33) | 243/689 (35) |
| CONKO-004 (2015)36 | Open label | LMWH: enoxaparin (1 mg/kg) for 3 mo, followed by 40 mg OD until disease progression | Nonresectable advanced pancreatic cancer | 312 | 298 (96)* | 5/154 (3) | 21/144 (15) | 13/154 (8) | 10/144 (7) | 48/154 (31) | 48/144 (33) |
| ABEL (2013)37 | Open label | Ultra LMWH: bemiparin (3500 IU) OD for 26 wk or until disease progression | Limited disease small-cell lung cancer | 39 | 19 (49) | 0/11 (0) | 0/8 (0) | 0/11 (0) | 1/8 (13) | 1/11 (9) | 2/8 (25) |
| SAVE-ONCO (2012)35 | Double blind | Ultra LMWH: semuloparin (20 mg) OD during chemotherapy | Locally advanced or metastatic cancer of lung, pancreas, stomach, colon, bladder, or ovary | 3212 | 1,551 (48) | 12/764 (2) | 30/787 (4) | 9/764 (2) | 11/787 (1) | 198/764 (26) | 242/787 (31) |
| . | . | . | . | . | . | VTE, n/N (%) . | Major bleeding, n/N (%) . | All-cause mortality, n/N (%) . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study . | Design . | Intervention . | Cancer type . | Randomized patients, n . | Khorana score ≥2, n (%) . | Prophylaxis . | Control . | Prophylaxis . | Control . | Prophylaxis . | Control . |
| CASSINI (2019)15 | Double blind | DOAC: rivaroxaban (10 mg) OD for 6 mo | Solid tumor or lymphoma | 841 | 841 (100) | 25/420 (6) | 37/421 (9) | 8/405 (2) | 4/404 (1) | 84/420 (20) | 100/421 (24) |
| AVERT (2019)14 | Double blind | DOAC: apixaban (2.5 mg) BID for 6 mo | Various types of new diagnoses or progressive solid cancers | 574 | 574 (100) | 12/291 (4) | 28/283 (10) | 6/288 (2) | 3/275 (1) | 35/291 (12) | 27/283 (10) |
| FRAGMATIC (2016)38 | Open label | LMWH: dalteparin (5000 IU) OD for 24 wk | Primary bronchial small-cell or non–small-cell carcinoma | 2202 | 1,343 (61) | 26/654 (4) | 45/689 (7) | 9/654 (2) | 13/689 (2) | 219/654 (33) | 243/689 (35) |
| CONKO-004 (2015)36 | Open label | LMWH: enoxaparin (1 mg/kg) for 3 mo, followed by 40 mg OD until disease progression | Nonresectable advanced pancreatic cancer | 312 | 298 (96)* | 5/154 (3) | 21/144 (15) | 13/154 (8) | 10/144 (7) | 48/154 (31) | 48/144 (33) |
| ABEL (2013)37 | Open label | Ultra LMWH: bemiparin (3500 IU) OD for 26 wk or until disease progression | Limited disease small-cell lung cancer | 39 | 19 (49) | 0/11 (0) | 0/8 (0) | 0/11 (0) | 1/8 (13) | 1/11 (9) | 2/8 (25) |
| SAVE-ONCO (2012)35 | Double blind | Ultra LMWH: semuloparin (20 mg) OD during chemotherapy | Locally advanced or metastatic cancer of lung, pancreas, stomach, colon, bladder, or ovary | 3212 | 1,551 (48) | 12/764 (2) | 30/787 (4) | 9/764 (2) | 11/787 (1) | 198/764 (26) | 242/787 (31) |
BID, twice daily; OD, once daily.
Khorana score could not be calculated in 14 patients.